Established in April 2005, KinoPharma is a pharmaceutical company engaged in research and development of drugs in collaboration with Kyoto University. The company is developing kinase inhibitors for viral infections, indication-wise cervical dysplasia, common warts, epidemic keratoconjunctivitis (first priority and advanced), and HBV, as well as neurodegenerative diseases, Alzheimer's disease and others.
| Website | http://kinopharma.com |
| Revenue | $5 million |
| Employees | 2 (2 on RocketReach) |
| Founded | 2005 |
| Address | 5-25-16 Hongo Bunkyo-ku, Tokyo, Tokyo, JP |
| Phone | +81 3-5299-9711 |
| Fax | +61 3 6264 9046 |
| Industry | Business Services General, Pharmaceutical, Business Services, Health Care |
| Keywords | Kinase Inhibitors, Pharmaceutical Research, Drug Development, Antiviral Drugs, Viral Infections, Drug Discovery, Drug Candidates, Medicinal Chemistry, Pharmaceutical Innovation, Therapeutics, Biotechnology, Clinical Trials, Molecular Medicine, Life Sciences, Pharmaceutical Manufacturing, New Drug Applications, Oncology Research, Fda Approval, Healthcare |
| Competitors | Roche, Pfizer, Amgen, Bristol Myers Squibb, AstraZeneca, Novartis, AbbVie, Johnson & Johnson, Merck AH, Lilly India +40 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Kinopharma Inc. employee's phone or email?
Kinopharma Inc. Questions
The Kinopharma Inc. annual revenue was $5 million in 2026.
Masafumi Kuroishi is the CEO of Kinopharma Inc..
2 people are employed at Kinopharma Inc..
Kinopharma Inc. is based in Tokyo, Tokyo.
The NAICS codes for Kinopharma Inc. are [32541, 325, 32, 3254].
The SIC codes for Kinopharma Inc. are [283, 28].
Top Kinopharma Inc. Employees
